Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders

Lawrence Scahill, James T. McCracken, Karen Bearss, Fay Robinson, Eric Hollander, Bryan King, Joel Bregman, Lin Sikich, Kimberly Dukes, Lisa Sullivan, Evdokia Anagnostou, Craig Donnelly, Young Shin Kim, Louise Ritz, Deborah Hirtz, Ann Wagner

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The Studies to Advance Autism Research and Treatment Network conducted a randomized trial with citalopram in children with Pervasive developmental disorders (PDDs). We present the rationale, design and sample characteristics of the citalopram trial. Subjects (128 boys, 21 girls) had a mean age of 9.3 (±3.12) years; 132 (88.6%) were diagnosed with autistic disorder (4.7% with Asperger's Disorder; 6.7% with PDD-not otherwise specified). Less than half of the subjects were intellectually disabled; 117 (78.5%) were rated Moderate or Marked on the Clinical Global Impression for Severity. Study measures were similar to previous Research Units on Pediatric Psychopharmacology trials. Subjects in this trial were slightly older and more likely to have complaints of repetitive behavior than participants in RUPP trials.

Original languageEnglish (US)
Pages (from-to)432-440
Number of pages9
JournalJournal of Autism and Developmental Disorders
Volume42
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Citalopram
Autistic Disorder
Asperger Syndrome
Psychopharmacology
Research
Pediatrics
Therapeutics

Keywords

  • Autism
  • Citalopram
  • Double-blind method
  • Repetitive behavior
  • Serotonin reuptake inhibitors

ASJC Scopus subject areas

  • Developmental and Educational Psychology

Cite this

Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders. / Scahill, Lawrence; McCracken, James T.; Bearss, Karen; Robinson, Fay; Hollander, Eric; King, Bryan; Bregman, Joel; Sikich, Lin; Dukes, Kimberly; Sullivan, Lisa; Anagnostou, Evdokia; Donnelly, Craig; Kim, Young Shin; Ritz, Louise; Hirtz, Deborah; Wagner, Ann.

In: Journal of Autism and Developmental Disorders, Vol. 42, No. 3, 03.2012, p. 432-440.

Research output: Contribution to journalArticle

Scahill, L, McCracken, JT, Bearss, K, Robinson, F, Hollander, E, King, B, Bregman, J, Sikich, L, Dukes, K, Sullivan, L, Anagnostou, E, Donnelly, C, Kim, YS, Ritz, L, Hirtz, D & Wagner, A 2012, 'Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders', Journal of Autism and Developmental Disorders, vol. 42, no. 3, pp. 432-440. https://doi.org/10.1007/s10803-011-1251-8
Scahill, Lawrence ; McCracken, James T. ; Bearss, Karen ; Robinson, Fay ; Hollander, Eric ; King, Bryan ; Bregman, Joel ; Sikich, Lin ; Dukes, Kimberly ; Sullivan, Lisa ; Anagnostou, Evdokia ; Donnelly, Craig ; Kim, Young Shin ; Ritz, Louise ; Hirtz, Deborah ; Wagner, Ann. / Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders. In: Journal of Autism and Developmental Disorders. 2012 ; Vol. 42, No. 3. pp. 432-440.
@article{cfe94810a5594b24b6f908b59bc3f11d,
title = "Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders",
abstract = "The Studies to Advance Autism Research and Treatment Network conducted a randomized trial with citalopram in children with Pervasive developmental disorders (PDDs). We present the rationale, design and sample characteristics of the citalopram trial. Subjects (128 boys, 21 girls) had a mean age of 9.3 (±3.12) years; 132 (88.6{\%}) were diagnosed with autistic disorder (4.7{\%} with Asperger's Disorder; 6.7{\%} with PDD-not otherwise specified). Less than half of the subjects were intellectually disabled; 117 (78.5{\%}) were rated Moderate or Marked on the Clinical Global Impression for Severity. Study measures were similar to previous Research Units on Pediatric Psychopharmacology trials. Subjects in this trial were slightly older and more likely to have complaints of repetitive behavior than participants in RUPP trials.",
keywords = "Autism, Citalopram, Double-blind method, Repetitive behavior, Serotonin reuptake inhibitors",
author = "Lawrence Scahill and McCracken, {James T.} and Karen Bearss and Fay Robinson and Eric Hollander and Bryan King and Joel Bregman and Lin Sikich and Kimberly Dukes and Lisa Sullivan and Evdokia Anagnostou and Craig Donnelly and Kim, {Young Shin} and Louise Ritz and Deborah Hirtz and Ann Wagner",
year = "2012",
month = "3",
doi = "10.1007/s10803-011-1251-8",
language = "English (US)",
volume = "42",
pages = "432--440",
journal = "Journal of Autism and Developmental Disorders",
issn = "0162-3257",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders

AU - Scahill, Lawrence

AU - McCracken, James T.

AU - Bearss, Karen

AU - Robinson, Fay

AU - Hollander, Eric

AU - King, Bryan

AU - Bregman, Joel

AU - Sikich, Lin

AU - Dukes, Kimberly

AU - Sullivan, Lisa

AU - Anagnostou, Evdokia

AU - Donnelly, Craig

AU - Kim, Young Shin

AU - Ritz, Louise

AU - Hirtz, Deborah

AU - Wagner, Ann

PY - 2012/3

Y1 - 2012/3

N2 - The Studies to Advance Autism Research and Treatment Network conducted a randomized trial with citalopram in children with Pervasive developmental disorders (PDDs). We present the rationale, design and sample characteristics of the citalopram trial. Subjects (128 boys, 21 girls) had a mean age of 9.3 (±3.12) years; 132 (88.6%) were diagnosed with autistic disorder (4.7% with Asperger's Disorder; 6.7% with PDD-not otherwise specified). Less than half of the subjects were intellectually disabled; 117 (78.5%) were rated Moderate or Marked on the Clinical Global Impression for Severity. Study measures were similar to previous Research Units on Pediatric Psychopharmacology trials. Subjects in this trial were slightly older and more likely to have complaints of repetitive behavior than participants in RUPP trials.

AB - The Studies to Advance Autism Research and Treatment Network conducted a randomized trial with citalopram in children with Pervasive developmental disorders (PDDs). We present the rationale, design and sample characteristics of the citalopram trial. Subjects (128 boys, 21 girls) had a mean age of 9.3 (±3.12) years; 132 (88.6%) were diagnosed with autistic disorder (4.7% with Asperger's Disorder; 6.7% with PDD-not otherwise specified). Less than half of the subjects were intellectually disabled; 117 (78.5%) were rated Moderate or Marked on the Clinical Global Impression for Severity. Study measures were similar to previous Research Units on Pediatric Psychopharmacology trials. Subjects in this trial were slightly older and more likely to have complaints of repetitive behavior than participants in RUPP trials.

KW - Autism

KW - Citalopram

KW - Double-blind method

KW - Repetitive behavior

KW - Serotonin reuptake inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84858798067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858798067&partnerID=8YFLogxK

U2 - 10.1007/s10803-011-1251-8

DO - 10.1007/s10803-011-1251-8

M3 - Article

VL - 42

SP - 432

EP - 440

JO - Journal of Autism and Developmental Disorders

JF - Journal of Autism and Developmental Disorders

SN - 0162-3257

IS - 3

ER -